| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.092 | 0.02 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | 0.099 | 0.02 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |